Revance Therapeutics, Inc.

Climate Impact & Sustainability Data (2022)

Total Energy Consumption:4,737,700 kWh/year

Water Consumption:1,200 gallons/day (average); 5,540 gallons/day (maximum)

Waste Generated:~100 gallons of mixed electronic waste/year; ~15 cubic feet of solid waste/week

Installed LED lighting in Newark office and moved headquarters to a LEED-certified building in Nashville (60% of office buildings are now LEED-certified)
Reduced energy use by installing LED lighting and using occupancy and daylight sensors

93% response rate in 2022 culture survey, achieving a 78% overall engagement score (vs. global benchmark of 72%)
Launched Leadership Edge for Women and Lab to Leader programs
Expanded mentorship program
Met 100% of corporate people goals in 2022 for the second consecutive year (related to D&I)
Improved family planning reimbursement account benefit to be more inclusive

Increased board diversity (25% ethnic diversity, 38% female representation)
Formed an ESG steering committee
Conducted first ESG materiality assessment and enterprise risk management assessment
Tied a portion of corporate and executive compensation to the achievement of people and D&I goals
Completed first pay equity assessment
Added responsible drug promotion practices to Code of Business Conduct and Ethics
Adopted political contributions policy and director overboarding policy
Adopted executive compensation clawback policy

Medium-term Goals:

Short-term Goals:

Greater-than-normal employee turnover (24.5% in 2022, attributed in part to the COVID-19 pandemic and delays in DAXXIFY® approval)
Improving work processes and communication of company strategy

Built an internal talent acquisition team with robust training for hiring managers
Implemented processes to remove biases in hiring
Organized a cross-functional leadership team to improve communication
Investing in system and process mapping exercises

Rigorous supplier selection process based on technical, quality, and regulatory requirements; due diligence for new suppliers; compliance with GMP guidelines and FDA regulations

Frameworks Used: SASB

DAXXIFY® (formulation free of human serum albumin or animal-based components); recyclable packaging for DAXXIFY® (planned for 2023)